Guest Editors should submit the proposal for a Thematic Issue in an area of considerable current interest to Bentham Science for approval. The proposal should contain the following information:
Tentative title of the Special Issue
One page proposal containing information about the importance of the specific area and the proposed date of submission of the articles
Sub topics of the Thematic Issue (typically 8 to 10 articles)
List of potential contributors (who should all be eminent in the field) along with their affiliations.
Tentative time schedule
In case there are more than one Guest Editors in a special issue, one Guest Editor will serve as the corresponding Editor.
The Guest Editor nominates authors to Bentham, and once they have been approved, invites them to submit papers for the special thematic issue which are of high quality in terms of science and presentation.
Papers submitted for the special or thematic issues are evaluated on the same strict criteria as regular contributed submissions. Each paper must be independently assessed by at least 2 (preferably 3) eminent experts in the field. Evidence for ;
(a) the review process (including names, designations and email addresses of the referees)
(b) evidence for the appropriate modification of the papers as suggested by the referees, and
(c) final acceptance by ALL the referees of the modified manuscripts should be provided to the publisher.
Guest editors take the initial decisions on the acceptance /rejection / revision and resubmission of manuscripts and relay the decision to the editorial office. In selected cases, the papers may be reviewed independently by Bentham and the publisher retains the right to accept or reject the manuscripts. Papers will only be published if they clearly merit publication on the basis of their originality and overall importance of results. Final editorial decisions on all Special/Thematic Issue submissions are generally taken by the Editors-in-Chief of the journal , but are subject to final approval by Bentham Science.
The contributors should be eminent researchers able to give a current overview of the latest developments in the field.
A Guest Editor/Co-Guest Editor may be an author or a co-author in only one manuscript. The guest Editor is also expected to write the Introduction to the issue.
It is recommended that only eminent contributing authors are selected from different regions.
An invitation to submit a paper to a special or thematic issue does not imply guaranteed acceptance for publication. Some submissions may be rejected.
It is a condition of publication that manuscripts submitted to Bentham should not have been published and should not be simultaneously submitted or published elsewhere, and should conform to the ethical guide lines (see https://benthamscience.com/publishing-ethics-main.php).
Guest Editors are required to convey the complete table of contents and the outline of the issue as well as the names and designations of contributing authors before the proposal is tentatively accepted (final acceptance being dependent on the review process). Guest Editors should inform the authors of the proposed time schedule for the Special Thematic Issue and if articles are not submitted in time to the Publisher than they may be eliminated.
Peer Review of Special/Thematic Issue Papers
Our editorial policy requires a minimum of two single-blind reviews for submitted articles.
Selection Criteria: A reviewer must hold a PhD degree and should normally have an h-index above 10.
Reviewers need to be approved by the Publisher prior to sending the articles for review by the Guest Editor.
Peer review of special/thematic issue papers should be conducted by eminent reviewers who are completely independent.
Reviewers cannot be selected from the contributing authors or from among the Guest Editors.
Final editorial decisions on all Special/Thematic Issue submissions will be decided by the Editors-in-Chief.
Bentham Science may carry out independent peer review and reserves the right to reject articles on the basis of such peer review.
When the referee reports have been received, the Guest Editors will be asked to make an initial decision, and where necessary, the paper will be sent back to the authors for revision. Once the Guest Editors have recommended to accept or reject a paper, the final decision will rest with the Editor‐in‐Chief. The editorial office will inform authors of the final status of the paper.
Once the papers have been accepted by the Editor, they are then transmitted to the publisher’s production department. Proofs will be available online for the authors to review and approve before Online publication.
Pennsylvania Drug Discovery Institute
Dr. Gross received a masters (M.S.) in Biology from the California State University and his doctorate (Ph.D.) in Cell Biology from the University of California, Los Angeles. He did his postdoctoral training at Tulane University School of Medicine. He has also done postgraduate programs at the Wharton School, Harvard/Tufts Law Schools and MIT. Dr. Gross is also faculty in the Jefferson College of Biomedical Sciences and the Sydney Kimmel Medical College of Thomas Jefferson University, Professor of Experimental Therapeutics and Medicinal Chemistry in the Blumberg Institute and Adjunct Professor of Basic Sciences at The Commonwealth Medical College. He has published more than 120 scientific publications. He currently is also the CEO of the Pennsylvania Drug Discovery Institute.
Dr. Beyer is President & CEO of Promentis Pharmaceuticals, Inc. He has nearly 20 years of experience in the research, discovery and business development of medications aimed to treat CNS and neurological disorders. Previously, Dr. Beyer served as the Head of Neurochemistry at Wyeth Pharmaceuticals in Princeton, NJ. During his career at Wyeth, Dr. Beyer holds a Ph.D. in Neuropharmacology from LSU Medical Center and an MBA from the Rutgers Business School. Notably, Dr. Beyer has authored more than 70 manuscripts, 3 patents, and co-edited "Next Generation Antidepressants." Dr. Beyer is also an adjunct faculty member at Thomas Jefferson University in Philadelphia where he teaches "Bioventure Management", a class focused on the business of doing science.
Pennsylvania Drug Discovery Institute
Dr. Reitz obtained a doctorate (Ph.D.) in Chemistry from the University of California, San Diego. Dr. Reitz also holds an Executive Masters in Technology Management from the University of Pennsylvania (Wharton, Penn Engineering).
Currently Dr. Reitz is also an Adjunct Professor in the Drexel University College of Medicine. He has published more than 150 scientific publications and is a named inventor of 60 issued U.S patents.
Dr. Reitz was the founding Editor (2000) and is currently the Editor-in-Chief of this
journal (Current Topics in Medicinal Chemistry, CTMC), published by Bentham
The Wistar Institute
Dr. Steinman holds a doctorate in biomedical sciences from the University of Massachusetts Medical School and an MBA from the university’s Isenberg School of Management. She graduated Summa Cum Laude from Baldwin-Wallace College with dual degrees in biology and psychology in the honors program.
Heather Steinman, Ph.D., MBA, is Vice President for Business Development and Executive Director of Technology Transfer at The Wistar Institute, the nation’s first independent research institution devoted solely to biomedical science and a world leader in cancer, immunology, virology and infectious disease research.
Dr. Steinman brings more than 18 years of experience in technology transfer and commercialization of early stage-life science discoveries.
University of Kentucky
Dr. Vanderford received a doctorate (Ph.D.) in Biochemistry from the University of Kentucky and he also holds a Master of Business Administration (MBA) degree. Dr. Vanderford holds a number of positions at the University of Kentucky including: Assistant Professor in the Department of Toxicology and Cancer Biology; Instructor in the Graduate School; Assistant Dean for Academic Development in the College of Medicine; and the Assistant Director for Research for the Markey Cancer Center. He has published his work in a number of prestigious journals including Science, Nature, and Nature Biotechnology. In addition to serving as Associate Editor for Technology Transfer and Entrepreneurship, he is also the Deputy Editor for the Journal of Research Administration.
University of San Francisco
Dr. Moira Gunn is an Associate Professor at University of San Francisco. She did her MS in Computer
Science and PhD in Mechanical Engineering from Purdue University, Lafayette, IN, USA. Dr. Gunn has
been teaching courses at the University of San Francisco since 1979. She was the Director of Information
Systems Program in USF from 2007 to 2009. She is the leader of Business of Biotechnology Program in
USF School of Management. She received Educator of the Year award from EE Times in 2008. She has
also received Public Service Award for contribution to the public understanding of science and
engineering from National Science Board in 2011.
Academic Technology Transfer
UWM Research Foundation
Dr. Jessica Silvaggi received her Ph.D. in Biochemistry from the Department
of Molecular and Cellular Biology at Harvard University, and conducted a
post-doctoral fellowship at the Dana Farber Cancer Institute. She has been
with the UWM Research Foundation since 2009, and is currently the Senior
Licensing Manager where she evaluates new inventions, manages the patent,
marketing, and licensing programs, and aids in teaching students and faculty
about new start-up formation. Dr. Silvaggi became a certified licensing
professional in 2014, and she enjoys growing the technology transfer
program at UWMRF while helping to increase the level of entrepreneurship
Editorial Board Members
Aurora Research Institute
Dr. Garrison earned his Ph.D. in Biological Sciences - Neuroscience from the University of Wisconsin, Milwaukee (USA) before completing his postdoctoral training in sensory biology at the Medical College of Wisconsin, Milwaukee (USA). He has previously worked with successful start-up companies in drug development, biotech consulting and bioinformatics. Currently, Dr. Garrison serves as a Research Scientist for the Aurora Research Institute, Aurora Health Care, and is the Wisconsin State Leader for the National Organization for Rare Disorders (NORD).
Leason Ellis LLP
ELIZABETH M. BARNHARD is Chair of the Pharma/Biotech Practice Group at Leason Ellis. With her many years of pharma industry and law firm experience, she works closely with clients to create and manage robust intellectual property portfolios that add value to their businesses. She is experienced in transactional and licensing work, in all phases of litigation and appeals of patent, trademark, copyright and unfair competition actions, and in patentability, freedom-to-operate, infringement, validity, product and manufacturing patent clearances in the areas of oncology/immunology, infectious diseases, virology, central nervous system disorders, cardiovascular/metabolic disorders, and molecular genetics.
Drexel University College of Medicine
Dr. James E. Barrett, Professor in the Department of Neurology, Pharmacology and Physiology and former Chair, Drexel University College of Medicine. He received his Ph.D. from Pennsylvania State University with postdoctoral training in neuropsychopharmacology at the Worcester Foundation for Experimental Biology. Dr. Barrett was Vice President of Neuroscience Discovery Research at Wyeth, Senior Vice President and Chief Scientific Officer, Adolor Corporation and Memory Pharmaceuticals. He has received several awards for significant contributions to pharmacology. He is a member of the Executive Committee of the IUPHAR. His current research emphasis is on pain and the development of novel therapeutics.
Dirección de Vinculación Tecnológica - CONICET
Dr Berenstein is Advisor to Vicepresident from CONICET and independent consultant in Technology transfer and Biobusiness for Scientific Community, Industry and Investment groups.. With more than 20 years of experience both in Research and tecnology transfer, she also held Management level positions in both public institutions and private companies in the Life Science Industry. She was previously ViceDirector, General Manager, and Director of leading Offices of Technology transfer and Bioincubators in Argentina (CONICET and Instituto Leloir) . Dr Berenstein holds a PhD in Gene therapy from University of Buenos Aires and an MBA from University of San Andrés. She is also Academic Director and Professor of Postgraduates courses in Pharma and Biotechnology Business from leading business Universities in Argentina.
National Institute of Pharmaceutical Education and Research
Dr. Asit K. Chakraborti is Professor and Head of the Department of Medicinal Chemistry, NIPER, S. A. S. Nagar, Punjab, India. He received Ph. D. degree in Synthetic Organic Chemistry from the Indian Association for the Cultivation of Science (IACS), Kolkata, India. He has published 166 research papers (with > 7600 citation and h index of 51) and filed 42 patents. He received several awards and recognition such as University Gold Medal, Bardhaman Sammilani Gold Medal, ISMAS Eminent Mass-spectroscopist Award, etc. He is the Fellow of the Royal Society of Chemistry and Indian Science Academies.
Case Western Reserve University
Dr. Cullis is the Francis Hobart Herrick Professor of Biology at Case Western Reserve University and Director of the Biotechnology Entrepreneurship Master’s Program. He is currently President of the Society for Bioentrepreneurship Education and Research (SIBER). His research has focused primarily on rapid genomic variation in plants. He is also currently working on developing a wild legume (marama, Tylosema esculentum) into a crop for resource poor farmers in Southern Africa. He has served as a program director at the National Science Foundation, on grant review panels, advisory and on editorial advisory boards of multiple journals.
Dakin Capital Services
Karl Dakin has 38 years in innovation commercialization. Mr. Dakin is a respected educator, extraordinary communicator, visionary leader with an entrepreneurial spirit and a small business advocate. Mr. Dakin is engaged in multiple new product, business and economic development projects. At the crossroads of capital and food, he is leading the development of a new democratized capital ecosystem within the State of Colorado where everyone can invest in Main Street businesses and he is increasing local food production by development, sale and operation of turnkey indoor agriculture systems.
Daniel is President of Promentis Pharmaceuticals, Inc., a biopharma company developing new therapies for the treatment of CNS disorders. Daniel was previously Group President at Dohmen, where he led five Dohmen group companies in the life science services space.
Daniel was General Counsel of Schwarz Pharma Inc. and previously at Abbott Laboratories where he was Senior Counsel to both the domestic and international organizations.
Daniel is a graduate of the University of Michigan and Harvard Law School, and was a Teaching Fellow in economics at Harvard College.
University of Arizona
Nina Ossanna, PhD holds a PhD in Molecular Biology and is a registered US patent agent. She is a founder and VP Business Development for Pharos Diagnostics and owner of Sonora Bioconsulting. She also Chairs the Bioindustry Organization of Southern Arizona. She has worked in university tech transfer directing offices at Johns Hopkins Medical School and the University of Arizona as well as working in start-up life science companies.
Dr. Ozsolak is an Associate Director at Vertex Pharmaceuticals. He previously worked at Biogen and RaNA Therapeutics, contributing to the discovery and development of drugs to treat CNS, liver and kidney diseases via small molecule and oligotherapeutics approaches. He obtained his PhD in biological chemistry and molecular pharmacology from Harvard University, and BA in biochemistry from Washington University in St. Louis.
Harvard Medical School
Frederick J. Schoen, M.D., Ph.D., is Professor of Pathology and Health Sciences and Technology (HST) at Harvard Medical School, and Executive Vice-Chairman of the Department of Pathology at Brigham and Women's Hospital (BWH). His research focuses on native and substitute heart valves. In institutional roles, he promotes multidisciplinary innovation using technology, provides mentoring and career development leadership for translational research, and teaches Pathology, Biomaterials, Tissue Engineering and Medical Device Development. He serves on the Massachusetts Life Sciences Center SAB, and many academic and governmental advisory, grant review and editorial committees, and consults with medical device companies.
University of California
Dr. Stahl obtained his MD from Northwestern University, his PhD in pharmacology from the University of Chicago and his postdoctoral trainin in Internal Medicine from the University of Chicago, in Neurology from the University of California San Francisco and in Psychiatry from Stanford University. Currently Dr. Stahl is a professor of psychiatry at the University of California San Diego and an Honorary Fellow at the University of Cambridge (UK). He serves as editor-in-chief of CNS Spectrums and is director of psychopharmacology for the California Department of State Hospitals. Author of over 500 papers, 35 textbooks and 12 edited books, Dr.
Stahl is an internationally recognized expert in psychopharmacology.
Medical College of Wisconsin
Dr. Tezlaff did her B.A. from University of Wisconsin-Milwaukee, Milwaukee, WI, USA; Ph.D. from Loyola
University Chicago, Maywood, IL, USA; and Postdoctorate from Massachusetts General Hospital of the
Harvard Medical School, Boston, MA, USA. She worked as a scientist at Seaside Therapeutics,
Cambridge, MA from 2008 till 2011. In 2011, she joined Department of Pathology of the Medical College
of Wisconsin and has been working there as an Assistant Professor since then. She has also been serving
as the Assistant Dean of Postdoctoral Education at the Medical College of Wisconsin since 2014. Her
research interest includes Sudden Infant Death Syndrome, Infant Mortality, Neuroscience, Biomarkers,
Professional and career development and Entrepreneurial initiatives.
Colorado State University
Dr. Tobet obtained a master’s degree (S.M.) and doctorate (Ph.D.) in Applied Biological Sciences from the Massachusetts Institute of Technology in Cambridge, MA. After 14 years in Boston as faculty at Harvard Medical School and then University of Massachusetts Medical School, he moved to Colorado State University (CSU) as a Professor in the College of Veterinary Medicine and Biomedical Sciences in 2003. In 2010 he was named the Director of the CSU School of Biomedical Engineering. He has published more than 135 papers in scientific journals. At CSU he helped create and deliver courses in Biomedical Entrepreneurship, Grant Writing, and STEM Communication.